1,164 reports of this reaction
3.2% of all INTERFERON BETA 1B reports
#5 most reported adverse reaction
MULTIPLE SCLEROSIS is the #5 most commonly reported adverse reaction for INTERFERON BETA 1B, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 1,164 FDA adverse event reports linking INTERFERON BETA 1B to MULTIPLE SCLEROSIS. This represents approximately 3.2% of all 36,175 adverse event reports for this drug.
Patients taking INTERFERON BETA 1B who experience multiple sclerosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE SCLEROSIS is moderately reported among INTERFERON BETA 1B users, representing a notable but not dominant share of adverse events.
In addition to multiple sclerosis, the following adverse reactions have been reported for INTERFERON BETA 1B:
The following drugs have also been linked to multiple sclerosis in FDA adverse event reports:
MULTIPLE SCLEROSIS has been reported as an adverse event in 1,164 FDA reports for INTERFERON BETA 1B. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE SCLEROSIS accounts for approximately 3.2% of all adverse event reports for INTERFERON BETA 1B, making it a notable side effect.
If you experience multiple sclerosis while taking INTERFERON BETA 1B, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.